<DOC>
	<DOCNO>NCT02158182</DOCNO>
	<brief_summary>The aim study determine whether lactulose , L-ornithine L-aspartate , rifaximin effective prevention development hepatic encephalopathy cirrhotic patient acute variceal bleeding</brief_summary>
	<brief_title>Lactulose , L-ornithine L-aspartate , Rifaximin Versus Placebo Preventing Hepatic Encephalopathy Variceal Bleeding</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>N-Methylaspartate</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Cirrhotic patient acute variceal bleeding , without minimal clinical hepatic encephalopathy accord PHES , CFF WestHaven criterion Age 18 yearold 65 yearold , neuropsychiatric disorder dementia , presence active bacterial fungal infection , receive antibiotic cause , previous diagnosis hepatic encephalopathy receive therapy lactulose , rifaximin , Lornithine Laspartate , source bleed different variceal origin , serum creatinine great 2.0 mg/dl chronic renal failure . Therapy previous six month drug use clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hepatic Encephalopathy</keyword>
	<keyword>Acute Variceal Bleeding</keyword>
	<keyword>Cirrhosis</keyword>
</DOC>